SAVE THE DATE!
SAVE THE DATE! Wir freuen uns, mitzuteilen, dass die 14. Internationalen VPM-Tage am Donnerstag und Freitag, 28. und 29. September 2023, im TWINCORE in Hannover stattfinden werden.
moreVPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients
VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients Vakzine Projekt Management GmbH (VPM) announced today that it…
moreVPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana
VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana. Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the…
moreVPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG
VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG We are pleased to announce the successful completion of a clinical client…
morePress release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases
VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases 01 December 2022VPM Hannover/Germany and Serum Institute of India Results of a novel tuberculosis vaccine tested in a large phase III trial…
moreVPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly
VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly We are pleased to announce that our VPM1002 trial, where VPM1002 was given as a prophylaxis…
moreVPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM.
On 15-16 September 2022, VPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM. We are very proud to be able to welcome more than…
moreArticle about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau
Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.
moreTuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.